Kyverna Therapeutics, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-38.3M | $-39.7M | $-37.8M | $-36.8M | $-42.1M | $-44.6M | $-37.5M | $-34.5M |
| Depreciation & Amortization | $300.0K | $351.0K | $698.0K | $300.0K | $300.0K | $501.0K | $1.1M | $300.0K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $3.5M | $3.2M | $2.7M | $2.7M | $2.5M | $2.2M | $1.4M | $3.4M |
| Net Cash from Operating Activities | $-40.3M | $-41.6M | $-33.5M | $-43.3M | $-31.9M | $-44.9M | $-37.1M | $-27.5M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | $-1.0K | $2.0K | $4.0K | $0 | $532.0K | $102.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $36.1M | $-50.2M | $-17.3M | $22.6M | $29.2M | $5.6M | $29.2M | $676.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $3.8M | $-101.0K | $140.7M | $1.5M | $-649.0K | $-414.0K | $-215.0K | $-152.0K |
| Net Change in Cash | $-388.0K | $-91.9M | $89.9M | $-19.3M | $-3.4M | $-39.8M | $-8.1M | $-27.0M |
| Free Cash Flow | — | — | $-33.5M | $-43.3M | $-32.0M | $-44.9M | $-37.6M | $-27.6M |